High concentrations of FGF23, increased inflammation and iron deficiency have been reported to be associated with increased risk of CVD and progression of CKD, poor skeletal integrity, low bone mineral density (BMD) and bone loss [9–11] and alterations of sclerostin (SOST) and RANKL, regulators of Wnt signalling [12, 13]. The gene discussed is FGF23; the disease is chronic kidney disease.